Skip to content

Medicine Matters

Sharing successes, challenges and daily happenings in the Department of Medicine

Medicine Matters Home Rheumatology

Rheumatology

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

ARTICLE: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) AUTHORS: Michelle Petri, Ian N Bruce, Thomas Dörner, Yoshiya Tanaka, Eric… Read More »Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)